Searchable abstracts of presentations at key conferences in endocrinology

ea0098c26 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

A pilot study of pembrolizumab and embolization or 90Y radioembolization for patients with metastatic well-differentiated neuroendocrine tumors

Fidelman MD Nicholas , Fong MD Lawrence , Zhang PhD Li , Bergsland MD Emily K.

Background: Well-differentiated neuroendocrine tumors (WD-NET) have a relatively low tumor mutation burden and do not commonly express the programmed death ligand 1 (PD-L1), characteristics which may limit the anti-tumor activity of PD-L1 inhibitors in this disease. Response rate to single agent immune checkpoint inhibitors (ICI) for patients with G1-3 NET is <15%. The intensity of anti-tumor immune response may be enhanced by addition of liver-directed therapy (LDT), such...

ea0098c19 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

The Impact of Post-Treatment Imaging in Peptide Receptor Radionuclide Therapy

Yadav, MD Surekha , Lawhn-Heath, MD Courtney , Lindsay, NP Sheila , Mirro, RN Rebecca , Bergsland, MD Emily K. , A Hope, MD Thomas

Background: A small portion (11%) of radioactive decay of 177Lu involves the emission of gamma photons, allowing for post-treatment imaging. Despite this capability, most centers do not routinely conduct post-treatment imaging. It is not well recognized that qualitative findings from post-PRRT imaging can influence clinical management. The aim of this study was to evaluate the rate of change in management from post treatment imaging.Methods: 100 patients...

ea0098c25 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

A pilot study of pembrolizumab and peptide receptor radionuclide therapy for patients with metastatic well-differentiated neuroendocrine tumors

Fidelman MD Nicholas , Keenan MD, PhD Bridget P. , Oh MD David Y. , Fong MD Lawrence , Chan BS Kira , Zhang PhD Li , Bergsland MD Emily K. , Hope MD Thomas A.

Background: Expected progression free survival (PFS) for patients with grade 3 well-differentiated neuroendocrine tumors (WD NET) treated with peptide receptor radionuclide therapy (PRRT) is approximately 9 months, and objective response rate (ORR) is 35%. Response rate to single agent immune checkpoint inhibitors (ICI) for patients with G1-3 NET is <15%. Delivery of targeted radiation using PRRT may potentiate the anti-tumor immune response. The purpose of this study is t...

ea0089o1 | Other | NANETS2022

Efficacy and Toxicity of Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Tyrosine Kinase Inhibitors (TKIs) in Neuroendocrine Tumors (NETs) – A Systematic Review and Meta-Analysis

Das, MD, MSCI Satya , Phillips, MSPH Sharon , M Lebeck Lee, MD Cody , Agarwal, MD, MSCI Rajiv , Bergsland, MD Emily , Strosberg, MD Jonathan , A. Chan, MD, MPH Jennifer , LaFerriere, MLIS Heather , A. Ramirez, DO Robert , Berlin, MD Jordan , Arvind Dasari, MD, MS and

Background: Although anti-VEGF RTKIs have been tested in patients with NETs over the last 2 decades, no study to date has benchmarked efficacy and toxicity of these drugs in this patient population.Methods: A literature search was performed to identify all phase II and phase III studies of anti-VEGF RTKIs in patients with NETs published between January 1, 2000 – July 31, 2021. Major trial databases (e.g. Medline, EMBASE, Cumulative Index of Nursing ...

ea0098p10 | Population Science | NANETS2023

Quality of life differs by age and sex for participants with advanced neuroendocrine neoplasms in the eNET study

Mulvey Claire K. , Paciorek Alan , Steiding Paige , Moon Farhana , Zhang Li , Bergsland Emily K.

Background: Patients with neuroendocrine neoplasms (NENs) have a high burden of chronic symptoms. We assessed symptom burden and overall quality of life (QOL) for eNET study participants and analyzed differences by age, sex, and NEN primary site.Methods: eNET is a prospective, cohort study on the Eureka digital health platform enrolling individuals with advanced NENs. Participants completed validated surveys on an internet-supported device at baseline an...

ea0089p7 | Population Science | NANETS2022

Feasibility of e-NET: A Web-Based Health Platform to Investigate Quality of Life in Patients with Neuroendocrine Tumors

Mulvey Claire K. , Steiding Paige , Moon Farhana , Paciorek Alan , Zhang Li , Bergsland Emily K.

Background: Patients with neuroendocrine neoplasms (NENs) have chronic symptoms from hormone overproduction, tumor growth and metastasis, and side effects from prolonged treatment. We assessed the feasibility of using a digital health platform to recruit patients with NENs to evaluate symptoms and quality of life.Methods: eNET is a prospective, web-based, cohort study for patients with advanced NENs of any primary site, histologic grade, differentiation,...

ea0013s68 | A successful research career | SFEBES2007

MD VS PhD

Munir Alia

We are all aware of the current anxieties over the future of Academic Medicine and Modernising Medical Careers. 10 years ago the BMA cohort of 1995 Medical graduates: Medical Academic Career Intentions was performed. 545 doctors graduating in 1995 were followed up for 10 years. The key findings included: those doctors working in research were doing so to improve future career prospects or as a means to secure a National Training Number (NTN). However being in the transition pe...

ea0063p294 | Pituitary and Neuroendocrinology 1 | ECE2019

Menstrual dysfunction (MD) with ACTH dependent Cushing syndrome

Irgasheva Oydin , Yusupovna Khalimova Zamira

MD are the most frequent complaint of women with Cushing Syndrome at the time of diagnosis.Objective: To study the frequency of occurrence of MD in patients with Syndrome Cushing and to characterize their clinical and hormonal parallels. We investigated 34 women (average age of 27 years, variation in age from 18 to 30 years) with a newly identified ACTHA. The patients were divided into 4 groups: (1) the normal cycle is 26–31 days; (2) oligomenorrhea...

ea0098p5 | Population Science | NANETS2023

Higher serotonin levels from ileum neuroendocrine tumors are associated with mesenteric mass progression

Yogo Akitada , Paciorek Alan , Moon Farhan , Bergsland Emily K. , Alseidi Adnan , Adam Mohamed , Maker Ajay , Corvera Carlos , Hirose Kenzo , Nakakura Eric K.

Background: Serotonin produced by ileum neuroendocrine tumors (i-NETs) promotes development of the mesenteric mass (MM) associated with lymph node metastases. We previously reported that more extensive MM progression along the superior mesenteric vessels predicts a lower rate of complete surgical resection. In this study, we hypothesized that tumoral serotonin production is associated not only with the development of MM but also its progression, and we examined serotonin level...

ea0098p6 | Population Science | NANETS2023

The use of antidepressants is associated with mesenteric mass formation of ileum neuroendocrine tumors

Yogo Akitada , Paciorek Alan , Moon Farhan , Bergsland Emily K. , Alseidi Adnan , Adam Mohamed , Maker Ajay , Corvera Carlos , Hirose Kenzo , Nakakura Eric K.

Background: Serotonin production by ileum neuroendocrine tumors (i-NETs) is considered a critical mediator of the fibrotic reaction in mesenteric mass (MM)/ lymph node metastasis. Antidepressants modify serotonin dynamics: however, their role in MM formation is uncertain. We hypothesized that histories of antidepressant use affect MM formation. This study examined the correlation between antidepressant use and MM formation.Methods: One hundred eighty-two...